

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Re:	Application No. 10/559,996	)	<i>Confirmation No. 4587</i>
Filed:	October 4, 2006	)	
Applicants:	Ralf KRAHMER et al.	)	<hr/>
Title:	REAGENTS FOR MODIFYING BIOPHARMACEUTICALS, THE USE AND PRODUCTION THEREOF	)	This Restriction Requirement and Amendment was electronically filed on September 13, 2007 using the USPTO's EFS-Web.
Art Unit:	1654	)	
Examiner:	Ronald T. Niebauer	)	
Attorney Docket:	5942/87136	)	
Customer No.:	22242	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION AND AMENDMENT**

Sir:

In response to the office action dated August 17, 2007, in which the Examiner required and Election between Groups I, II and III . Applicants hereby elect with traverse Group I, claims 1-5, 9-15, and 17-20 and species where

Z= formula (X<sub>c</sub>),

in which a is 3, b is 2, c is 2, d is 3, P is H and R<sup>1</sup> is a C<sub>1</sub>-C<sub>10</sub> alkoxy residue; the disclosure therefor can be found in paragraph [0045] of the U.S. publication;

W= hydrogen;

X= short chain methoxy polyethylene residues having three ethylene units; the disclosure therefor can be found in paragraph [0044].

Application No. 10/559,996

RESTRICTION REQUIREMENT AND AMENDMENT dated September 13, 2007

Reply to Office Action of August 17, 2007

V= a hydrocarbon residue which contains heteroatoms and a linker group represented by an alkyl chain which contains the heteroatoms N and O. The disclosure therefor can be found in paragraphs [0048] and [0054].

The election is with traverse as the claims of Groups I, II and III are linked by a common inventive concept, namely compounds and/or a method of preparing compounds which exhibit at least two groups of formula (IIa). These compounds and the method for preparing such compounds are not anticipated by the prior art so that the common inventive concept is novel.

**Amendments to the Specification** begin on page 3 of this paper.

**Amendments to the Claims** begin on page 5 of this paper.

**Remarks/Arguments** begin on page 13 of this paper.